术后辅助化疗与既往结直肠癌患者结直肠腺瘤发生率降低相关
该回顾性研究纳入192例低风险II期结直肠癌根治术后患者,按年龄和性别匹配分为接受与未接受5-氟尿嘧啶为基础辅助化疗各96例。化疗组晚期腺瘤发生率显著低于非化疗组(3.1% vs 10.4%,P=.044),校正混杂因素后辅助化疗与晚期腺瘤发生率降低相关(OR .151,95%CI .035-.653,P=.011)。
要点
- 化疗组晚期腺瘤发生率为3.1%,非化疗组为10.4%,差异有统计学意义(P=.044)。
- 校正BMI、阿司匹林使用、二甲双胍使用、随访结肠镜次数和手术类型后,辅助化疗与晚期腺瘤发生率降低相关(OR .151,95%CI .035-.653,P=.011)。
- 化疗组任何结直肠腺瘤发生率为41.7%(40/96),非化疗组为52.1%(50/96)。
核心结论
- 结果表明,结直肠癌患者接受化疗可能与结直肠晚期腺瘤发生风险降低相关。
研究设计与样本
- 回顾性研究,从2006年至2013年间1808例接受根治性切除术后结肠镜监测的II期结直肠癌患者中,按年龄和性别匹配后纳入192例低风险II期患者,分为接受5-氟尿嘧啶为基础辅助化疗96例和未接受化疗96例。
主要发现
- 化疗组96例中40例(41.7%)检出结直肠腺瘤,非化疗组96例中50例(52.1%)检出结直肠腺瘤。
- 化疗组晚期腺瘤发生率为3.1%,非化疗组为10.4%,差异有统计学意义(P=.044)。
- 校正体质指数、阿司匹林使用、二甲双胍使用、随访结肠镜次数和手术类型后,辅助化疗与晚期腺瘤发生率降低相关(OR .151,95%CI .035-.653,P=.011)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The effects of chemotherapeutic agents on the development of colorectal adenomas in patients with previous colorectal cancer (CRC) are not defined. Therefore, we evaluated the potential effect of adjuvant chemotherapy on the incidence of colorectal adenomas in patients with previous CRC. METHODS: We selected patients with low-risk stage II CRC with or without postoperative 5-fluorouracil-based adjuvant chemotherapy to reduce selection bias. Among 1808 patients with stage II CRC who underwent colonoscopic surveillance after curative resection of CRC between 2006 and 2013, 192 patients were retrospectively enrolled in this study after matching for age and sex. The patients were divided into 96 patients receiving and 96 patients not receiving 5-fluorouracil-based chemotherapy. RESULTS: Forty patients (41.7%) exhibited colorectal adenomas among 96 patients who received adjuvant chemotherapy, compared with 50 patients (52.1%) with colorectal adenomas among 96 patients who received surgery only. The incidence rate of advanced adenoma was significantly lower in the chemotherapy group than in the nonchemotherapy group (3.1% vs 10.4%, P = .044). After adjustment for clinically relevant factors such as body mass index, aspirin use, metformin use, number of follow-up colonoscopies, and operation type, adjuvant chemotherapy was found to be associated with a decreased incidence of advanced adenoma (odds ratio, .151; 95% confidence interval, .035-.653; P = .011) in patients with stage II CRC. CONCLUSIONS: The results showed that chemotherapy in patients with CRC may be associated with a lower risk of colorectal advanced adenoma development.
引用
- Lee HS, Kim SB, Lee HJ, et al. Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer. Gastrointest Endosc. 2017. PMID: 28431950. doi:10.1016/j.gie.2017.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。